Cargando…
Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792375/ https://www.ncbi.nlm.nih.gov/pubmed/32998624 http://dx.doi.org/10.1161/JAHA.120.016871 |
_version_ | 1783633791417319424 |
---|---|
author | Pamidi, Sushmita Chapotot, Florian Wroblewski, Kristen Whitmore, Harry Polonsky, Tamar Tasali, Esra |
author_facet | Pamidi, Sushmita Chapotot, Florian Wroblewski, Kristen Whitmore, Harry Polonsky, Tamar Tasali, Esra |
author_sort | Pamidi, Sushmita |
collection | PubMed |
description | BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP). To date, no prior study has assessed the effect of CPAP treatment on daytime resting heart rate, a strong predictor of adverse cardiovascular outcomes and mortality. METHODS AND RESULTS: We conducted a randomized controlled study in 39 participants with OSA and prediabetes, who received either in‐laboratory all‐night (ie, optimal) CPAP or an oral placebo for 2 weeks. During daytime, participants continued daily activities outside the laboratory. Resting heart rate was continuously assessed over 19 consecutive days and nights using an ambulatory device consisting of a single‐lead ECG and triaxis accelerometer. Compared with placebo, CPAP reduced daytime resting heart rate (treatment difference, −4.1 beats/min; 95% CI, −6.5 to −1.7 beats/min; P=0.002). The magnitude of reduction in daytime resting heart rate after treatment significantly correlated with the magnitude of decrease in plasma norepinephrine, a marker of sympathetic activity (r=0.44; P=0.02), and the magnitude of decrease in OSA severity (ie, apnea‐hypopnea index [r=0.48; P=0.005], oxygen desaturation index [r=0.50; P=0.003], and microarousal index [r=0.57; P<0.001]). CONCLUSIONS: This proof‐of‐concept randomized controlled study demonstrates, for the first time, that CPAP treatment, when optimally used at night, reduces resting heart rate during the day, and therefore has positive cardiovascular carry over effects. These findings suggest that better identification and treatment of OSA may have important clinical implications for cardiovascular disease prevention. REGISTRATION: URL: https:/// www.clinicaltrials.gov; Unique identifier: NCT01156116. |
format | Online Article Text |
id | pubmed-7792375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77923752021-01-15 Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study Pamidi, Sushmita Chapotot, Florian Wroblewski, Kristen Whitmore, Harry Polonsky, Tamar Tasali, Esra J Am Heart Assoc Brief Communication BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP). To date, no prior study has assessed the effect of CPAP treatment on daytime resting heart rate, a strong predictor of adverse cardiovascular outcomes and mortality. METHODS AND RESULTS: We conducted a randomized controlled study in 39 participants with OSA and prediabetes, who received either in‐laboratory all‐night (ie, optimal) CPAP or an oral placebo for 2 weeks. During daytime, participants continued daily activities outside the laboratory. Resting heart rate was continuously assessed over 19 consecutive days and nights using an ambulatory device consisting of a single‐lead ECG and triaxis accelerometer. Compared with placebo, CPAP reduced daytime resting heart rate (treatment difference, −4.1 beats/min; 95% CI, −6.5 to −1.7 beats/min; P=0.002). The magnitude of reduction in daytime resting heart rate after treatment significantly correlated with the magnitude of decrease in plasma norepinephrine, a marker of sympathetic activity (r=0.44; P=0.02), and the magnitude of decrease in OSA severity (ie, apnea‐hypopnea index [r=0.48; P=0.005], oxygen desaturation index [r=0.50; P=0.003], and microarousal index [r=0.57; P<0.001]). CONCLUSIONS: This proof‐of‐concept randomized controlled study demonstrates, for the first time, that CPAP treatment, when optimally used at night, reduces resting heart rate during the day, and therefore has positive cardiovascular carry over effects. These findings suggest that better identification and treatment of OSA may have important clinical implications for cardiovascular disease prevention. REGISTRATION: URL: https:/// www.clinicaltrials.gov; Unique identifier: NCT01156116. John Wiley and Sons Inc. 2020-10-01 /pmc/articles/PMC7792375/ /pubmed/32998624 http://dx.doi.org/10.1161/JAHA.120.016871 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Communication Pamidi, Sushmita Chapotot, Florian Wroblewski, Kristen Whitmore, Harry Polonsky, Tamar Tasali, Esra Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title | Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title_full | Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title_fullStr | Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title_full_unstemmed | Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title_short | Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study |
title_sort | optimal continuous positive airway pressure treatment of obstructive sleep apnea reduces daytime resting heart rate in prediabetes: a randomized controlled study |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792375/ https://www.ncbi.nlm.nih.gov/pubmed/32998624 http://dx.doi.org/10.1161/JAHA.120.016871 |
work_keys_str_mv | AT pamidisushmita optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy AT chapototflorian optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy AT wroblewskikristen optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy AT whitmoreharry optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy AT polonskytamar optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy AT tasaliesra optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy |